$CARSGEN-B(02171)$ Reindeer Bi

$CARSGEN-B(02171)$ Reindeer Bio’s FukeSu was successfully launched in mainland China in 2023, attracting patients from over 10 countries to come for treatment.

The market response has been strong, and the NDA applications in Hong Kong and Singapore have been swiftly submitted, paving the way for Khezi’s CT041 international launch.

The biggest strength of CT041 lies in its potential for a cure, offering immense hope for patients. Although its overall ORR and PFS are not as high as autologous treatments, the efficacy in early-line treatment for patients with high CLDN18.2 expression is promising, and the upcoming post-surgery adjuvant therapy data suggests a significant expansion in its treatment potential.

As it gradually expands into global markets, CT041 represents not just a glimmer of hope, but a shining new star in the pharmaceutical field.

Winning Trades

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":404638889480408,"tweetId":"404638889480408","gmtCreate":1739792497444,"gmtModify":1739792503947,"author":{"id":3479274730958210,"idStr":"3479274730958210","authorId":3479274730958210,"authorIdStr":"3479274730958210","name":"historyiong","avatar":"https://static.tigerbbs.com/673f24849e790c3aa318f19aa443d828","vip":8,"userType":8,"introduction":"运营账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":72,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/9bc24da9315ad74c640611217f0b13d7","width":"696","height":"1122"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/9bc24da9315ad74c640611217f0b13d7","width":"696","height":"1122"}],"html":"<html><head></head><body> <a data-mention-id=\"02171\" class=\"teditor-mention\" data-mention-name=\"CARSGEN-B\" href=\"https://ttm.financial/S/02171\">$CARSGEN-B(02171)$</a> Reindeer Bio’s FukeSu was successfully launched in mainland China in 2023, attracting patients from over 10 countries to come for treatment. The market response has been strong, and the NDA applications in Hong Kong and Singapore have been swiftly submitted, paving the way for Khezi’s CT041 international launch. The biggest strength of CT041 lies in its potential for a cure, offering immense hope for patients. Although its overall ORR and PFS are not as high as autologous treatments, the efficacy in early-line treatment for patients with high CLDN18.2 expression is promising, and the upcoming post-surgery adjuvant therapy data suggests a significant expansion in its treatment potential. As it gradually expands into global markets, CT041 represents not just a glimmer of hope, but a shining new star in the pharmaceutical field.<img src=\"https://community-static.tradeup.com/news/9bc24da9315ad74c640611217f0b13d7\" tg-width=\"696\" tg-height=\"1122\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"02171\" class=\"teditor-mention\" data-mention-name=\"CARSGEN-B\" href=\"https://ttm.financial/S/02171\">$CARSGEN-B(02171)$</a> Reindeer Bio’s FukeSu was successfully launched in mainland China in 2023, attracting patients from over 10 countries to come for treatment. The market response has been strong, and the NDA applications in Hong Kong and Singapore have been swiftly submitted, paving the way for Khezi’s CT041 international launch. The biggest strength of CT041 lies in its potential for a cure, offering immense hope for patients. Although its overall ORR and PFS are not as high as autologous treatments, the efficacy in early-line treatment for patients with high CLDN18.2 expression is promising, and the upcoming post-surgery adjuvant therapy data suggests a significant expansion in its treatment potential. As it gradually expands into global markets, CT041 represents not just a glimmer of hope, but a shining new star in the pharmaceutical field.<img src=\"https://community-static.tradeup.com/news/9bc24da9315ad74c640611217f0b13d7\" tg-width=\"696\" tg-height=\"1122\"></body></html>","text":"$CARSGEN-B(02171)$ Reindeer Bio’s FukeSu was successfully launched in mainland China in 2023, attracting patients from over 10 countries to come for treatment. The market response has been strong, and the NDA applications in Hong Kong and Singapore have been swiftly submitted, paving the way for Khezi’s CT041 international launch. The biggest strength of CT041 lies in its potential for a cure, offering immense hope for patients. Although its overall ORR and PFS are not as high as autologous treatments, the efficacy in early-line treatment for patients with high CLDN18.2 expression is promising, and the upcoming post-surgery adjuvant therapy data suggests a significant expansion in its treatment potential. As it gradually expands into global markets, CT041 represents not just a glimmer of hope, but a shining new star in the pharmaceutical field.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/404638889480408","repostId":0,"isVote":1,"tweetType":1,"viewCount":634,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02171"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":726,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/404638889480408"}